Jay Feingold - 14 Apr 2022 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Chief Medical Officer
Signature
/s/ Pamela Connealy, Attorney-in-Fact for Jay Feingold
Issuer symbol
PYXS
Transactions as of
14 Apr 2022
Net transactions value
$0
Form type
4
Filing time
15 Apr 2022, 19:58:23 UTC
Previous filing
04 Apr 2022
Next filing
03 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PYXS Common Stock Award $0 +115,931 +33% $0.000000 466,611 14 Apr 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date.
F2 The Compensation Committee also approved a grant to the Reporting Person, effective January 3, 2023, of an additional 53,931 RSUs that vest on April 13, 2023, subject to the Reporting Person's continued employment through the grant and vesting dates.